- Novel biologic investigational therapeutic: recombinant fusion protein containing the soluble TACI receptor that binds to the cytokines BLyS and APRIL, members of the tumor necrosis factor family that stimulate B cells and plasma cells to produce autoantibodies associated with IgA nephropathy (IgAN)1 and lupus nephritis (LN)2
- Well-tolerated safety profile in clinical studies including >1,500 patients across multiple indications3
- Self-administered once weekly by 1-mL subcutaneous injection
- Vera holds an exclusive worldwide license for the development and commercialization of atacicept in all indications from Merck KGaA, Darmstadt, Germany, a leading science and technology company
BLyS = B lymphocyte stimulator, also known as B-cell activating factor or BAFF; APRIL = A proliferation-inducing ligand; TACI = transmembrane activator and CAML interactor.
1Macpherson AJ, et al. Mucosal Immunol 2008; 2Dillon SR, et al. Arthritis Res Ther 2010; 3Gordon C, et al. Rheumatol Adv Pract 2019 and data on file.